GSK partners with Duality Biologics in a $30 million upfront deal, potentially worth $975 million, for access to a ...

Versant is out with its third obesity biotech of the year, leading an €80 million Series A for Antag Therapeutics, a Danish ...

Eli Lilly has removed the commonly used clinical measure of body mass index from the FDA label for its weight loss drug ...

Cartesian Therapeutics reported longer-term results from a mid-stage study of its mRNA CAR-T therapy for myasthenia gravis, ...

Ipsen has inked yet another licensing deal in an effort to bolster its cancer pipeline, this time for a preclinical T cell ...

The SEC said Tuesday that it settled charges filed against Kiromic Biopharma, a tiny immuno-oncology startup based in Texas, ...

Relay Therapeutics licenses lirafugratinib to Elevar Therapeutics for $75m upfront and milestone payments, with potential ...

Coherus BioSciences' stock surged on Tuesday after the company announced plans to sell off the last biosimilar in its ...

Roivant reported a Phase 2 failure on Tuesday for a program analysts expected would not succeed. The compound in question, ...

GSK has axed a Phase 2 study of a chronic hepatitis B therapeutic vaccine, adding to a string of treatment R&D hurdles for the liver infection.

Bristol Myers Squibb partners with AI Proteins for miniprotein development, with up to $400M in milestones. Terns Pharmaceuticals reports positive Phase 1 data for TERN-701. Six biotechs seek Hong ...

In response to lawmakers' concerns, Pfizer and Eli Lilly said last week that they do not influence telehealth partners and ...